Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Precancerous Conditions 3Neuroblastoma 3Skin Neoplasms 2Prostatic Neoplasms 2Carcinoma, Basal Cell 2Adenomatous Polyposis Coli 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Non-melanoma Skin Cancer 1Keratosis, Actinic 1Gastritis, Atrophic 1Esophageal Neoplasms 1Colorectal Neoplasms 1Adenomatous Polyps 1

Interventions

Celecoxib 4Surveys and Questionnaires 2Sulindac 2Erlotinib Hydrochloride 2Endoscopy 2Eflornithine 2Curcumin 2Biopsy 2guselkumab 1Ursodeoxycholic Acid 1Suppositories 1Sirolimus 1Sigmoidoscopy 1Metformin 1Lithium Carbonate 1Gastroscopy 1Endoscopy, Digestive System 1Eicosapentaenoic Acid 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Adenomatous Polyposis Coli × Eflornithine × Clear all
NCT01483144 2021-06-08

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Completed
171 enrolled 13 charts
Gastrointestinal

Adenomatous Polyposis Coli

NCT00033371 2020-09-29

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Completed
205 enrolled 16 charts
Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡